Please select an option below to help us tailor your newsletter to best suit your content interests!
A prospective, multi-center, randomized, double-arm trial to determine the impact of the SELENE system on positive margin rates in breast conservation surgery
VIEW TRIAL ON CLINICALTRIALS.GOVBreast
Stage 2
Phase 2
Open to Enrollment
First line
Selene
Optical Coherence Tomography (OCT)
Richard Fine, MD
PERIMETER
Inclusion Criteria:
Exclusion Criteria:
Phase II Trial Evaluating the Efficacy and Safety of Neoadjuvant Neratinib and Chemotherapy in Early Stage Triple-Negative Breast Cancer Patients Who Exhibit Enhanced HER2 Signaling by Live Cell HER2 Signaling Transduction Analysis (FACT-2)
VIEW TRIAL ON CLINICALTRIALS.GOVBreast, Triple Negative Breast Cancer
Stage 2
Phase 2
Open to Enrollment
Neoadjuvant
Neratinib
HER2 targeted small molecule
Greg Vidal, MD, PhD
West Cancer Center, Puma Biotechnology, Celcuity
ER negative, PR negative, HER2 negative
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
VIEW TRIAL ON CLINICALTRIALS.GOVBreast cancer, HER2 positive
Stage 2
Phase 3
Open to Enrollment
N/A
Atezolizumab
PD-L1 inhibitor
Greg Vidal, MD, PhD
Roche/Genentech
HER2 positive early breast cancer
A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (DatoDXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)
VIEW TRIAL ON CLINICALTRIALS.GOVBreast, Triple negative breast cancer, TNBC
Stage 3
Phase 3
Open to Enrollment
Adjuvant
datopotamab deruxtecan (Dato-DXd)
ADC, Trop2 with Topo1 inhibitor payload
Greg Vidal, MD, PhD
AstraZeneca
Triple negative, ER negative, PR negative, HER2 negative
A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Patients With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
VIEW TRIAL ON CLINICALTRIALS.GOVBreast Cancer, MBC, IBC
Stage 4
Phase 3
Open to Enrollment
2nd line endocrine
Giredestrant
SERD
Greg Vidal, MD, PhD
Genentech, Inc.
ER positive, HER2 negative
A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Giredestrant in Combination With Phesgo Versus Phesgo After Induction Therapy With Phesgo + Taxane in Patients With Previously Untreated HER2-Positive, Estrogen Receptor-Positive Locally-Advanced or Metastatic Breast Cancer
VIEW TRIAL ON CLINICALTRIALS.GOVBreast cancer, IBC
Stage 4
Phase 3
Open to Enrollment
1st
Giredestrant, Phesgo, taxane
SERD, anti-HER2
Saradasri Wellikoff, MD
Roche
HER2 positive, ER positive
Phase III Study of Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09)
VIEW TRIAL ON CLINICALTRIALS.GOVBreast cancer, IBC
Stage 4
Phase 3
Open to Enrollment
1st Line
Trastuzumab Deruxtecan
Anti-body drug conjugate against HER2
Greg Vidal, MD, PhD
AstraZeneca
HER2+ (IHC 3+ or FISH+)
A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1
VIEW TRIAL ON CLINICALTRIALS.GOVBreast cancer, IBC
Stage 4
Phase 3
Open to Enrollment
1st or 2nd line
Sacituzumab govitecan-hziy
Trop-2 antibody drug conjugate
Greg Vidal, MD, PhD
Gilead Sciences
Triple negative; TNBC
A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced, Inoperable, or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1
VIEW TRIAL ON CLINICALTRIALS.GOVBreast cancer, IBC
Stage 4
Phase 3
Open to Enrollment
1st line
Sacituzumab govitecan, pembrolizumab
Trop-2 antibody drug conjugate, PD-1 inhibitor
Greg Vidal, MD, PhD
Gilead Sciences
TNBC, PD-L1 positive
A Phase 1b/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Triple-Negative Breast Cancer
VIEW TRIAL ON CLINICALTRIALS.GOVBreast, Triple Negative Breast Cancer, TNBC
Stage 4
Phase 1
Open to Enrollment
2nd Line
Atezolizumab with Ipatasertib or ladiratuzumab-vidotin or Bevacizumab or Cobimetinib or Capecitabine or Combination Chemo
PD-L1 antibody with either PI3Ki or LIV1A ADC or MEKi or VEGFRi or chemo
Greg Vidal, MD, PhD
Hoffman-La Roche
ER- (negative), PR- (negative), HER2- (negative)
A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes.
VIEW TRIAL ON CLINICALTRIALS.GOVBreast, lung, colon, prostate, bladder, RCC, kidney, skin, melanoma, gastric, pancreatic, HCC, rectal, sarcoma, head and neck, esophagus, biliary tract
Stage 4
Phase 2
Open to Enrollment
Last line
nab-sirolimus
MTOR inhibitor
Dan Vaena, MD
Aadi Bioscience, Inc.
TSC1 or TSC2 alterations
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors
VIEW TRIAL ON CLINICALTRIALS.GOVRenal cell carcinoma, hormone receptor positive breast cancer, castration-resistant prostate cancer, urothelial cancer, colorectal cancer (HR+ BC, RCC, CRPC, Bladder, CRC)
Stage 4
Phase 1
Open to Enrollment
Generally at least 1 prior line. Some exceptions
XL092
VEGF/MET kinase inhibitor
Dan Vaena, MD
Exelixis
A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
VIEW TRIAL ON CLINICALTRIALS.GOVEsophageal, Gastric, Cervical, clear cell renal cell cancer, RCC, hepatocellular carcinoma, HCC, liver cancer, HNSCC, head and neck cancer, oropharyngeal, larynx, hypopharyngeal, oral cavity, melanoma, urothelial carcinoma, bladder cancer, triple-negative breast cancer, TNBC, non-small cell lung cancer, NSCLC, colon, prostate
Stage 4
Phase 1
Open to Enrollment
>1st line
RO7502175
Anti-CCR8 antibody
Dan Vaena, MD
Genentech, Inc.
Carcinoma
A Phase 1/2, Open-Label, Dose-Escalation and Cohort-Expansion Study Evaluating the Safety, Pharmacokinetics, and Therapeutic Activity of OBI-999 in Patients With Advanced Solid Tumors
VIEW TRIAL ON CLINICALTRIALS.GOVPancreatic, Esophageal, Gastric, Colorectal, Breast, Lung, Prostate, Melanoma, Head and Neck, Sarcoma, Bladder, Renal Cell, Ovarian, Endometrial, Cervical
Stage 4
Phase 1
Open to Enrollment
Late line
OBI-999
Globo H targeting agent
Dan Vaena, MD
OBI Pharma
Any solid tumor